MX2019008813A - Composiciones para el tratamiento de la hipertension. - Google Patents
Composiciones para el tratamiento de la hipertension.Info
- Publication number
- MX2019008813A MX2019008813A MX2019008813A MX2019008813A MX2019008813A MX 2019008813 A MX2019008813 A MX 2019008813A MX 2019008813 A MX2019008813 A MX 2019008813A MX 2019008813 A MX2019008813 A MX 2019008813A MX 2019008813 A MX2019008813 A MX 2019008813A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- hypertension
- treatment
- dose
- lhtd
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 2
- 239000000480 calcium channel blocker Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 2
- 102000008873 Angiotensin II receptor Human genes 0.000 abstract 1
- 108050000824 Angiotensin II receptor Proteins 0.000 abstract 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003087 receptor blocking agent Substances 0.000 abstract 1
- 229960005187 telmisartan Drugs 0.000 abstract 1
- 238000011287 therapeutic dose Methods 0.000 abstract 1
- 239000005458 thiazide-like diuretic Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
En el presente documento se proporcionan composiciones farmacéuticas que son útiles para el tratamiento de la hipertensión, que comprende un bloqueador del receptor de angiotensina II, un diurético, y un bloqueador de los canales de calcio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762450324P | 2017-01-25 | 2017-01-25 | |
PCT/IB2018/000083 WO2018138578A1 (en) | 2017-01-25 | 2018-01-23 | Compositions for the treatment of hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019008813A true MX2019008813A (es) | 2020-02-12 |
Family
ID=62979058
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019008813A MX2019008813A (es) | 2017-01-25 | 2018-01-23 | Composiciones para el tratamiento de la hipertension. |
MX2023004366A MX2023004366A (es) | 2017-01-25 | 2019-07-24 | Composiciones para el tratamiento de la hipertension. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023004366A MX2023004366A (es) | 2017-01-25 | 2019-07-24 | Composiciones para el tratamiento de la hipertension. |
Country Status (22)
Country | Link |
---|---|
US (5) | US10322117B2 (es) |
EP (3) | EP4374915A2 (es) |
JP (2) | JP2020506180A (es) |
KR (1) | KR20190127691A (es) |
CN (2) | CN116327958A (es) |
AU (2) | AU2018213147B2 (es) |
BR (1) | BR112019015368A2 (es) |
CA (1) | CA3051374A1 (es) |
DK (1) | DK3573620T3 (es) |
ES (1) | ES2940316T3 (es) |
FI (1) | FI3573620T3 (es) |
HR (1) | HRP20230267T1 (es) |
HU (1) | HUE061444T2 (es) |
LT (1) | LT3573620T (es) |
MX (2) | MX2019008813A (es) |
PL (1) | PL3573620T3 (es) |
PT (1) | PT3573620T (es) |
RS (1) | RS64042B1 (es) |
RU (1) | RU2019126749A (es) |
SI (1) | SI3573620T1 (es) |
TW (3) | TW201831204A (es) |
WO (1) | WO2018138578A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
WO2018138578A1 (en) | 2017-01-25 | 2018-08-02 | The George Institute for Global Health | Compositions for the treatment of hypertension |
WO2020041864A1 (en) * | 2018-08-25 | 2020-03-05 | Crd Pharmaceuticals Inc. | Synchronize hypertensive therapy with circadian rhythm |
CN111789843A (zh) * | 2019-04-08 | 2020-10-20 | 深圳奥萨医药有限公司 | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 |
CN113616651B (zh) * | 2020-05-08 | 2023-12-29 | 深圳奥萨制药有限公司 | 一种复方降压药物组合物及其应用 |
US11730706B1 (en) * | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
DE60119715T3 (de) | 2000-04-10 | 2016-12-08 | Nicholas John Wald | Zusammensetzung zur prävention kardiovaskulärer erkrankungen |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
WO2005070463A2 (en) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
EP1734958A1 (en) | 2004-04-06 | 2006-12-27 | Merck & Co., Inc. | Methods for the treatment of hypertension |
KR100582347B1 (ko) | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
US20070196510A1 (en) | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
US20070293552A1 (en) | 2006-06-15 | 2007-12-20 | Gorczynski Richard J | Antihypertensive therapy method |
JP2010536880A (ja) | 2007-08-22 | 2010-12-02 | ギリード・コロラド・インコーポレーテッド | 糖尿病の合併症のための療法 |
KR20090057538A (ko) * | 2007-12-03 | 2009-06-08 | 박사룡 | 안지오텐신 투 안타고니스트, 칼슘 안타고니스트 및이뇨제를 함유하는 고혈압 치료제 조성물 |
CN101450211A (zh) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | 复方降压制剂 |
DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
CN101966191A (zh) * | 2009-07-14 | 2011-02-09 | 邬林祥 | 一种治疗高血压含氨氯地平和替米沙坦的复方制剂 |
CN101618215A (zh) | 2009-08-16 | 2010-01-06 | 王丽燕 | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 |
WO2011149438A1 (en) * | 2010-05-28 | 2011-12-01 | Mahmut Bilgic | Combination of antihypertensive agents |
CN101966190A (zh) * | 2010-07-17 | 2011-02-09 | 邬林祥 | 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂 |
CN102225203A (zh) * | 2011-06-29 | 2011-10-26 | 北京阜康仁生物制药科技有限公司 | 一种用于降低血压的药用组合物 |
US10918612B2 (en) * | 2013-01-22 | 2021-02-16 | Markus Zwickl | Combinations with 2-aminoethanesulfonic acid |
CZ2015687A3 (cs) | 2015-10-02 | 2017-04-12 | Zentiva, K.S. | Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu |
CN106310278A (zh) * | 2016-08-01 | 2017-01-11 | 深圳奥萨制药有限公司 | 一种含叶酸的多联降压药物组合物 |
US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
WO2018138578A1 (en) | 2017-01-25 | 2018-08-02 | The George Institute for Global Health | Compositions for the treatment of hypertension |
WO2020021341A1 (en) | 2018-07-26 | 2020-01-30 | The George Institute for Global Health | Compositions for the treatment of hypertension |
-
2018
- 2018-01-23 WO PCT/IB2018/000083 patent/WO2018138578A1/en unknown
- 2018-01-23 EP EP24164449.1A patent/EP4374915A2/en active Pending
- 2018-01-23 EP EP18745362.6A patent/EP3573620B1/en active Active
- 2018-01-23 AU AU2018213147A patent/AU2018213147B2/en active Active
- 2018-01-23 HR HRP20230267TT patent/HRP20230267T1/hr unknown
- 2018-01-23 RS RS20230204A patent/RS64042B1/sr unknown
- 2018-01-23 PT PT187453626T patent/PT3573620T/pt unknown
- 2018-01-23 EP EP22188172.5A patent/EP4101454B1/en active Active
- 2018-01-23 JP JP2019539974A patent/JP2020506180A/ja active Pending
- 2018-01-23 HU HUE18745362A patent/HUE061444T2/hu unknown
- 2018-01-23 CA CA3051374A patent/CA3051374A1/en active Pending
- 2018-01-23 RU RU2019126749A patent/RU2019126749A/ru unknown
- 2018-01-23 MX MX2019008813A patent/MX2019008813A/es unknown
- 2018-01-23 KR KR1020197024682A patent/KR20190127691A/ko not_active IP Right Cessation
- 2018-01-23 CN CN202310463571.8A patent/CN116327958A/zh active Pending
- 2018-01-23 LT LTEPPCT/IB2018/000083T patent/LT3573620T/lt unknown
- 2018-01-23 SI SI201830873T patent/SI3573620T1/sl unknown
- 2018-01-23 DK DK18745362.6T patent/DK3573620T3/da active
- 2018-01-23 FI FIEP18745362.6T patent/FI3573620T3/fi active
- 2018-01-23 BR BR112019015368-3A patent/BR112019015368A2/pt active Search and Examination
- 2018-01-23 CN CN201880021071.6A patent/CN110545819A/zh active Pending
- 2018-01-23 PL PL18745362.6T patent/PL3573620T3/pl unknown
- 2018-01-23 ES ES18745362T patent/ES2940316T3/es active Active
- 2018-01-25 TW TW107102631A patent/TW201831204A/zh unknown
- 2018-01-25 TW TW112101171A patent/TW202319049A/zh unknown
- 2018-01-25 TW TW109105655A patent/TWI825279B/zh active
- 2018-03-13 US US15/919,923 patent/US10322117B2/en active Active
-
2019
- 2019-04-24 US US16/393,774 patent/US10799487B2/en active Active
- 2019-07-24 MX MX2023004366A patent/MX2023004366A/es unknown
-
2020
- 2020-09-08 US US17/014,358 patent/US11478462B2/en active Active
-
2022
- 2022-09-16 US US17/932,982 patent/US20230087834A1/en active Pending
- 2022-12-14 JP JP2022199757A patent/JP2023063282A/ja active Pending
-
2023
- 2023-08-08 US US18/446,268 patent/US20230381161A1/en active Pending
- 2023-11-27 AU AU2023274064A patent/AU2023274064A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023004366A (es) | Composiciones para el tratamiento de la hipertension. | |
MX2016008362A (es) | Combinaciones farmaceuticas. | |
CL2019002470A1 (es) | Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina. | |
EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
PH12019500202A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12019500206A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12019500207A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX2019001322A (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
MX2020003088A (es) | Composicion medicinal que comprende el inhibidor del sglt2 y el antagonista del receptor de angiotensina. | |
PH12021550048A1 (en) | Selective estrogen receptor degraders. | |
MX2017012068A (es) | Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos. | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
MX2022007391A (es) | Compuestos activos frente a receptores nucleares. | |
MX2023000677A (es) | Compuestos moduladores de receptor de estrogeno. | |
MX2021004883A (es) | Metodos y composiciones para tratar apnea del sue?o. | |
MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
EP4299120A3 (en) | Telmisartan for the prophylaxis or treatment of hypertension in cats | |
MX2021001043A (es) | Composiciones para el tratamiento de hipertension. | |
MX2017010630A (es) | Derivado de imidazopirimidina e imidazotriazina, y composicion farmaceutica que lo comprende. | |
MX2022000520A (es) | Compuestos moduladores del receptor de estrogeno. | |
WO2020013776A3 (en) | Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation |